Tocilizumab plus dexamethasone versus dexamethasone in patients with moderate-to-severe COVID-19 pneumonia : A randomised clinical trial from the CORIMUNO-19 study group
© 2022 The Author(s)..
Background: In moderate-to-severe COVID-19 pneumonia, dexamethasone (DEX) and tocilizumab (TCZ) reduce the occurrence of death and ventilatory support. We investigated the efficacy and safety of DEX+TCZ in an open randomized clinical trial.
Methods: From July 24, 2020, through May 18, 2021, patients with moderate-to-severe COVID-19 pneumonia requiring oxygen (>3 L/min) were randomly assigned to receive DEX (10 mg/d 5 days tapering up to 10 days) alone or combined with TCZ (8 mg/kg IV) at day 1, possibly repeated with a fixed dose of 400 mg i.v. at day 3. The primary outcome was time from randomization to mechanical ventilation support or death up to day 14, analysed on an intent-to-treat basis using a Bayesian approach. ClinicalTrials.gov number, NCT04476979.
Findings: A total of 453 patients were randomized, 3 withdrew consent, 450 were analysed, of whom 226 and 224 patients were assigned to receive DEX or TCZ+DEX, respectively. At day 14, mechanical ventilation or death occurred in 32/226 (14%) and 27/224 (12%) in the DEX and TCZ+DEX arms, respectively (hazard ratio [HR] 0·85, 90% credible interval [CrI] 0·55 to 1·31). At day 14, the World health Organization (WHO) clinical progression scale (CPS) was significantly improved in the TCZ+DEX arm (OR 0·69, 95% CrI, 0·49 to 0.97). At day 28, the cumulative incidence of oxygen supply independency was 82% in the TCZ+DEX arms and 72% in the DEX arm (HR 1·36, 95% CI 1·11 to 1·67). On day 90, 24 deaths (11%) were observed in the DEX arm and 18 (8%) in the TCZ+DEX arm (HR 0·77, 95% CI 0·42-1·41). Serious adverse events were observed in 25% and 21% in DEX and TCZ+DEX arms, respectively.
Interpretation: Mechanical ventilation need and mortality were not improved with TCZ+DEX compared with DEX alone. The safety of both treatments was similar. However, given the wide confidence intervals for the estimate of effect, definitive interpretation cannot be drawn.
Funding: Programme Hospitalier de Recherche Clinique [PHRC COVID-19-20-0151, PHRC COVID-19-20-0029], Fondation de l'Assistance Publique - Hôpitaux de Paris (Alliance Tous Unis Contre le Virus) and from Fédération pour la Recherche Médicale" (FRM). Tocilizumab was provided by Roche.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:46 |
|---|---|
| Enthalten in: |
EClinicalMedicine - 46(2022) vom: 10. Apr., Seite 101362 |
| Sprache: |
Englisch |
|---|
| Links: |
|---|
| Themen: |
COVID-19 |
|---|
| Anmerkungen: |
Date Revised 01.04.2022 published: Electronic-eCollection ClinicalTrials.gov: NCT04476979 Citation Status PubMed-not-MEDLINE |
|---|
| doi: |
10.1016/j.eclinm.2022.101362 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM338801790 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM338801790 | ||
| 003 | DE-627 | ||
| 005 | 20231226001504.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2022 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.eclinm.2022.101362 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1129.xml |
| 035 | |a (DE-627)NLM338801790 | ||
| 035 | |a (NLM)35350097 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Hermine, Olivier |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Tocilizumab plus dexamethasone versus dexamethasone in patients with moderate-to-severe COVID-19 pneumonia |b A randomised clinical trial from the CORIMUNO-19 study group |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 01.04.2022 | ||
| 500 | |a published: Electronic-eCollection | ||
| 500 | |a ClinicalTrials.gov: NCT04476979 | ||
| 500 | |a Citation Status PubMed-not-MEDLINE | ||
| 520 | |a © 2022 The Author(s). | ||
| 520 | |a Background: In moderate-to-severe COVID-19 pneumonia, dexamethasone (DEX) and tocilizumab (TCZ) reduce the occurrence of death and ventilatory support. We investigated the efficacy and safety of DEX+TCZ in an open randomized clinical trial | ||
| 520 | |a Methods: From July 24, 2020, through May 18, 2021, patients with moderate-to-severe COVID-19 pneumonia requiring oxygen (>3 L/min) were randomly assigned to receive DEX (10 mg/d 5 days tapering up to 10 days) alone or combined with TCZ (8 mg/kg IV) at day 1, possibly repeated with a fixed dose of 400 mg i.v. at day 3. The primary outcome was time from randomization to mechanical ventilation support or death up to day 14, analysed on an intent-to-treat basis using a Bayesian approach. ClinicalTrials.gov number, NCT04476979 | ||
| 520 | |a Findings: A total of 453 patients were randomized, 3 withdrew consent, 450 were analysed, of whom 226 and 224 patients were assigned to receive DEX or TCZ+DEX, respectively. At day 14, mechanical ventilation or death occurred in 32/226 (14%) and 27/224 (12%) in the DEX and TCZ+DEX arms, respectively (hazard ratio [HR] 0·85, 90% credible interval [CrI] 0·55 to 1·31). At day 14, the World health Organization (WHO) clinical progression scale (CPS) was significantly improved in the TCZ+DEX arm (OR 0·69, 95% CrI, 0·49 to 0.97). At day 28, the cumulative incidence of oxygen supply independency was 82% in the TCZ+DEX arms and 72% in the DEX arm (HR 1·36, 95% CI 1·11 to 1·67). On day 90, 24 deaths (11%) were observed in the DEX arm and 18 (8%) in the TCZ+DEX arm (HR 0·77, 95% CI 0·42-1·41). Serious adverse events were observed in 25% and 21% in DEX and TCZ+DEX arms, respectively | ||
| 520 | |a Interpretation: Mechanical ventilation need and mortality were not improved with TCZ+DEX compared with DEX alone. The safety of both treatments was similar. However, given the wide confidence intervals for the estimate of effect, definitive interpretation cannot be drawn | ||
| 520 | |a Funding: Programme Hospitalier de Recherche Clinique [PHRC COVID-19-20-0151, PHRC COVID-19-20-0029], Fondation de l'Assistance Publique - Hôpitaux de Paris (Alliance Tous Unis Contre le Virus) and from Fédération pour la Recherche Médicale" (FRM). Tocilizumab was provided by Roche | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a COVID-19 | |
| 650 | 4 | |a Randomized clinical trial | |
| 650 | 4 | |a Tocilizumab+Dexamethasone | |
| 700 | 1 | |a Mariette, Xavier |e verfasserin |4 aut | |
| 700 | 1 | |a Porcher, Raphael |e verfasserin |4 aut | |
| 700 | 1 | |a Djossou, Felix |e verfasserin |4 aut | |
| 700 | 1 | |a Nguyen, Yann |e verfasserin |4 aut | |
| 700 | 1 | |a Arlet, Jean-Benoît |e verfasserin |4 aut | |
| 700 | 1 | |a Savale, Laurent |e verfasserin |4 aut | |
| 700 | 1 | |a Diehl, Jean Luc |e verfasserin |4 aut | |
| 700 | 1 | |a Georgin-Lavialle, Sophie |e verfasserin |4 aut | |
| 700 | 1 | |a Cadranel, Jacques |e verfasserin |4 aut | |
| 700 | 1 | |a Pialoux, Gilles |e verfasserin |4 aut | |
| 700 | 1 | |a Lacombe, Karine |e verfasserin |4 aut | |
| 700 | 1 | |a Mekinian, Arsène |e verfasserin |4 aut | |
| 700 | 1 | |a Gros, Hélène |e verfasserin |4 aut | |
| 700 | 1 | |a Lescure, Xavier |e verfasserin |4 aut | |
| 700 | 1 | |a Ghosn, Jade |e verfasserin |4 aut | |
| 700 | 1 | |a Coupez, Elisabeth |e verfasserin |4 aut | |
| 700 | 1 | |a Grapin, Kevin |e verfasserin |4 aut | |
| 700 | 1 | |a Rapp, Christophe |e verfasserin |4 aut | |
| 700 | 1 | |a Michel, Marc |e verfasserin |4 aut | |
| 700 | 1 | |a Lecapitaine, Anne Lise |e verfasserin |4 aut | |
| 700 | 1 | |a Michot, Jean Marie |e verfasserin |4 aut | |
| 700 | 1 | |a Costedoat-Chalumeau, Nathalie |e verfasserin |4 aut | |
| 700 | 1 | |a Nguyen, Liem Binh Luong |e verfasserin |4 aut | |
| 700 | 1 | |a Semerano, Luca |e verfasserin |4 aut | |
| 700 | 1 | |a Raffi, François |e verfasserin |4 aut | |
| 700 | 1 | |a Aguillar, Claire |e verfasserin |4 aut | |
| 700 | 1 | |a Rouzaud, Claire |e verfasserin |4 aut | |
| 700 | 1 | |a Gottenberg, Jacques Eric |e verfasserin |4 aut | |
| 700 | 1 | |a Hansmann, Yves |e verfasserin |4 aut | |
| 700 | 1 | |a Bienvenu, Boris |e verfasserin |4 aut | |
| 700 | 1 | |a London, Jonathan |e verfasserin |4 aut | |
| 700 | 1 | |a Fantchou, Franklin Samou |e verfasserin |4 aut | |
| 700 | 1 | |a Ackermann, Felix |e verfasserin |4 aut | |
| 700 | 1 | |a Gros, Antoine |e verfasserin |4 aut | |
| 700 | 1 | |a Morel, Alexandre |e verfasserin |4 aut | |
| 700 | 1 | |a Gambier, Nicolas |e verfasserin |4 aut | |
| 700 | 1 | |a Sène, Damien |e verfasserin |4 aut | |
| 700 | 1 | |a Mégarbane, Bruno |e verfasserin |4 aut | |
| 700 | 1 | |a Azoulay, Elie |e verfasserin |4 aut | |
| 700 | 1 | |a Bureau, Serge |e verfasserin |4 aut | |
| 700 | 1 | |a Dougados, Maxime |e verfasserin |4 aut | |
| 700 | 1 | |a Emmerich, Joseph |e verfasserin |4 aut | |
| 700 | 1 | |a Fartoukh, Muriel |e verfasserin |4 aut | |
| 700 | 1 | |a Guidet, Bertrand |e verfasserin |4 aut | |
| 700 | 1 | |a Humbert, Marc |e verfasserin |4 aut | |
| 700 | 1 | |a Mahevas, Mathieu |e verfasserin |4 aut | |
| 700 | 1 | |a Pène, Frédéric |e verfasserin |4 aut | |
| 700 | 1 | |a Schlemmer, Frédéric |e verfasserin |4 aut | |
| 700 | 1 | |a Pourcher-Martinez, Valérie |e verfasserin |4 aut | |
| 700 | 1 | |a Tibi, Annick |e verfasserin |4 aut | |
| 700 | 1 | |a Baron, Gabriel |e verfasserin |4 aut | |
| 700 | 1 | |a Perrodeau, Elodie |e verfasserin |4 aut | |
| 700 | 1 | |a Baron, Stéphanie |e verfasserin |4 aut | |
| 700 | 1 | |a Steg, Gabriel |e verfasserin |4 aut | |
| 700 | 1 | |a Yazdapanah, Yazdan |e verfasserin |4 aut | |
| 700 | 1 | |a Simon, Tabassome |e verfasserin |4 aut | |
| 700 | 1 | |a Resche-Rigon, Matthieu |e verfasserin |4 aut | |
| 700 | 1 | |a Tharaux, Pierre-Louis |e verfasserin |4 aut | |
| 700 | 1 | |a Ravaud, Philippe |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t EClinicalMedicine |d 2018 |g 46(2022) vom: 10. Apr., Seite 101362 |w (DE-627)NLM289300495 |x 2589-5370 |7 nnns |
| 773 | 1 | 8 | |g volume:46 |g year:2022 |g day:10 |g month:04 |g pages:101362 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.eclinm.2022.101362 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 46 |j 2022 |b 10 |c 04 |h 101362 | ||